100% satisfaction guarantee Immediately available after payment Both online and in PDF No strings attached
Previously searched by you
Test Bank for Pharmacotherapeutics For Nurse Practitioner Prescribers 3Rd Edition by Teri Moser Woo, Anita Lee Wynne Chapter 1-50 |Updated 2024$19.49
Add to cart
Test Bank for Pharmacotherapeutics for Nurse Pract
Institution
Test Bank For Pharmacotherapeutics For Nurse Pract
Book
Pharmacotherapeutics for Nurse Practitioner Prescribers
Test Bank for Pharmacotherapeutics For Nurse Practitioner Prescribers 3Rd Edition by Teri Moser Woo, Anita Lee Wynne Chapter 1-50 |Complete Guide A+
Table of Content
Chapter 1: The Role of the Nurse Practitioner as Prescriber
Chapter 2: Review of Basic Principles of Pharmacology
Chapter 3: Rat...
pharmacotherapeutics for nurse practitioner prescribers 3rd edition by teri moser woo
pharmacotherapeutics for nurse practitioner prescribers 3rd edition by woo
Connected book
Book Title:
Author(s):
Edition:
ISBN:
Edition:
More summaries for
Test Bank for Pharmacotherapeutics for Nurse Practitioner Prescribers 3rd Edition by Woo A+
COMPLETE TEST BANK: Pharmacotherapeutics For Nurse Practitioner Prescribers Third Edition By Teri Moser Woo Rn Phd Arnp Cpnp-Pc Cnl Faanp (Author) latest Update.
TEST BANK Pharmacotherapeutics For Nurse Practitioner Prescribers 3rd Edition by Teri Moser Woo & Anita Lee Wynne , ISBN: 9780803622357 |All 52 Chapters Verified||Complete Guide A+|
All for this textbook (19)
Written for
Test Bank for Pharmacotherapeutics for Nurse Pract
All documents for this subject (1)
1
review
By: leannetucker820 • 2 year ago
Seller
Follow
solutions
Reviews received
Content preview
Test Bank for
Pharmacotherapeutics for Nurse Practitioner
Prescribers 3rd Edition
Author: Teri Moser Woo and Anita Lee Wynne
Table of Content
Chapter 1: The Role of the Nurse Practitioner as Prescriber
Chapter 2: Review of Basic Principles of Pharmacology
Chapter 3: Rational Drug Selection
Chapter 4: Legal and Professional Issues in Prescribing
Chapter 5: Adverse Drug Reactions
Chapter 6: Factors that Foster Positive Outcomes
Chapter 7: Cultural and Ethnic Influences in Pharmacotherapeutics
Chapter 8: An Introduction to Pharmacogenomics
Chapter 9: Nutrition and Nutraceuticals
Chapter 10: Herbal Therapy and Nutritional Supplements
Chapter 11: Information Technology and Pharmacotherapeutics
Chapter 12: Pharmacoeconomics
Chapter 13: Over-the-Counter Medications
Chapter 14: Drugs Affecting the Autonomic Nervous System
Chapter 15: Drugs Affecting the Central Nervous System
Chapter 16: Drugs Affecting the Cardiovascular and Renal Systems
Chapter 17: Drugs Affecting the Respiratory System
Chapter 18: Drugs Affecting the Hematopoietic System
Chapter 19: Drugs Affecting the Immune System
Chapter 20: Drugs Affecting the Gastrointestinal System
Chapter 21: Drugs Affecting the Endocrine System
Chapter 22: Drugs Affecting the Reproductive System
Chapter 23: Drugs Affecting the Integumentary System
Chapter 24: Drugs Used in Treating Infectious Diseases
Chapter 25: Drugs Used in Treating Inflammatory Processes
Chapter 26: Drugs Used in Treating Eye and Ear Disorders
Chapter 27: Anemia
Chapter 28: Chronic Stable Angina and Low-Risk Unstable Angina
Chapter 29: Anxiety and Depression
Chapter 30: Asthma and Chronic Obstructive Pulmonary Disease
Chapter 31: Contraception
Chapter 32: Dermatologic Conditions
Chapter 33: Diabetes Mellitus
Chapter 34: Gastroesophageal Reflux and Peptic Ulcer Disease
Chapter 35: Headaches
Chapter 36: Heart Failure
Chapter 37: Human Immunodeficiency Virus Disease and Acquired Immunodefiency Syndrome
Chapter 38: Hormone Replacement Therapy and Osteoporosis
Chapter 39: Hyperlipidemia
Chapter 40: Hypertension
Chapter 41: Hyperthyroidism and Hypothyroidism
Chapter 42: Pneumonia
Chapter 43: Smoking Cessation
Chapter 44: Sexually Transmitted Infections and Vaginitis
Chapter 45: Tuberculosis
Chapter 46: Upper Respiratory Infections: Otitis Media and Otitis Externa
Chapter 47: Urinary Tract Infections
Chapter 48: Women as Patients
Chapter 49: Men as Patients
Chapter 50: Pediatric Patients
Chapter 1: The Role of the Nurse Practitioner as Prescriber
Multiple Choice
Identify the choice that best completes the statement or answers the question.
,_ 1. Nurse practitioner prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing for each state
D. The State Board of Pharmacy
_ 2. Physician Assistant (PA) prescriptive authority is regulated by:
A. The National Council of State Boards of Nursing
B. The U.S. Drug Enforcement Administration
C. The State Board of Nursing
D. The State Board of Medical Examiners
_ 3. Clinical judgment in prescribing includes:
A. Factoring in the cost to the patient of the medication prescribed
B. Always prescribing the newest medication available for the disease process
C. Handing out drug samples to poor patients
D. Prescribing all generic medications to cut costs
_ 4. Criteria for choosing an effective drug for a disorder include:
A. Asking the patient what drug they think would work best for them
B. Consulting nationally recognized guidelines for disease management
C. Prescribing medications that are available as samples before writing a prescription
D. Following U.S. Drug Enforcement Administration (DEA) guidelines for
prescribing
_ 5. Nurse practitioner practice may thrive under health-care reform due to:
A. The demonstrated ability of nurse practitioners to control costs and improve patient
outcomes
B. The fact that nurse practitioners will be able to practice independently
C. The fact that nurse practitioners will have full reimbursement under health-care
reform
D. The ability to shift accountability for Medicaid to the state level
Chapter 1: The Role of the Nurse Practitioner as Prescriber
Answer Section
MULTIPLE CHOICE
1. ANS: C PTS: 1
2. ANS: D PTS: 1
3. ANS: A PTS: 1
4. ANS: B PTS: 1
5. ANS: A PTS: 1
Chapter 2: Review of Basic Principles of Pharmacology
Multiple Choice
Identify the choice that best completes the statement or answers the question.
_ 1. A patient’s nutritional intake and lab work reflects hypoalbuminemia. This is critical to
prescribing because:
A. Distribution of drugs to target tissue may be affected
B. The solubility of the drug will not match the site of absorption
C. There will be less free drug available to generate an effect
D. Drugs bound to albumin are readily excreted by the kidney
,_ 2. Drugs that have a significant first-pass effect:
A. Must be given by the enteral (oral) route only
B. Bypass the hepatic circulation
C. Are rapidly metabolized by the liver and may have little if any desired action
D. Are converted by the liver to more active and fat-soluble forms
_ 3. The route of excretion of a volatile drug will likely be:
A. The kidneys
B. The lungs
C. The bile and feces
D. The skin
_ 4. Medroxyprogesterone (Depo Provera) is prescribed IM to create a storage reservoir of the
drug. Storage reservoirs:
A. Assure that the drug will reach its intended target tissue
B. Are the reason for giving loading doses
C. Increase the length of time a drug is available and active
D. Are most common in collagen tissues
_ 5. The NP chooses to give cephalexin every 8 hours based on knowledge of the drug’s:
A. Propensity to go to the target receptor
B. Biological half-life
C. Pharmacodynamics
D. Safety and side effects
_ 6. Azithromycin dosing requires the first day’s dose be twice those of the other 4 days of the
prescription. This is considered a loading dose. A loading dose:
A. Rapidly achieves drug levels in the therapeutic range
B. Requires four to five half-lives to attain
C. Is influenced by renal function
D. Is directly related to the drug circulating to the target tissues
_ 7. The point in time on the drug concentration curve that indicates the first sign of a therapeutic
effect is the:
A. Minimum adverse effect level
B. Peak of action
C. Onset of action
D. Therapeutic range
_ 8. Phenytoin requires a trough level be drawn. Peak and trough levels are done:
A. When the drug has a wide therapeutic range
B. When the drug will be administered for a short time only
C. When there is a high correlation between the dose and saturation of receptor sites
D. To determine if a drug is in the therapeutic range
_ 9. A laboratory result indicates the peak level for a drug is above the minimum toxic
concentration. This means that the:
A. Concentration will produce therapeutic effects
B. Concentration will produce an adverse response
C. Time between doses must be shortened
D. Duration of action of the drug is too long
_ 10. Drugs that are receptor agonists may demonstrate what property?
A. Irreversible binding to the drug receptor site
B. Up-regulation with chronic use
C. Desensitization or down-regulation with continuous use
D. Inverse relationship between drug concentration and drug action
, _ 11. Drugs that are receptor antagonists, such as beta blockers, may cause:
A. Down-regulation of the drug receptor
B. An exaggerated response if abruptly discontinued
C. Partial blockade of the effects of agonist drugs
D. An exaggerated response to competitive drug agonists
_ 12. Factors that affect gastric drug absorption include:
A. Liver enzyme activity
B. Protein-binding properties of the drug molecule
C. Lipid solubility of the drug
D. Ability to chew and swallow
_ 13. Drugs administered via intravenous (IV) route:
A. Need to be lipid soluble in order to be easily absorbed
B. Begin distribution into the body immediately
C. Are easily absorbed if they are nonionized
D. May use pinocytosis to be absorbed
_ 14. When a medication is added to a regimen for a synergistic effect, the combined effect of the drugs
is:
A. The sum of the effects of each drug individually
B. Greater than the sum of the effects of each drug individually
C. Less than the effect of each drug individually
D. Not predictable, as it varies with each individual
_ 15. Which of the following statements about bioavailability is true?
A. Bioavailability issues are especially important for drugs with narrow therapeutic
ranges or sustained release mechanisms.
B. All brands of a drug have the same bioavailability.
C. Drugs that are administered more than once a day have greater bioavailability than
drugs given once daily.
D. Combining an active drug with an inert substance does not affect bioavailability.
_ 16. Which of the following statements about the major distribution barriers (blood-brain or fetal-
placental) is true?
A. Water soluble and ionized drugs cross these barriers rapidly.
B. The blood-brain barrier slows the entry of many drugs into and from brain cells.
C. The fetal-placental barrier protects the fetus from drugs taken by the mother.
D. Lipid soluble drugs do not pass these barriers and are safe for pregnant women.
_ 17. Drugs are metabolized mainly by the liver via Phase I or Phase II reactions. The purpose of both
of these types of reactions is to:
A. Inactivate prodrugs before they can be activated by target tissues
B. Change the drugs so they can cross plasma membranes
C. Change drug molecules to a form that an excretory organ can excrete
D. Make these drugs more ionized and polar to facilitate excretion
_ 18. Once they have been metabolized by the liver, the metabolites may be:
A. More active than the parent drug
B. Less active than the parent drug
C. Totally “deactivated” so that they are excreted without any effect
D. All of the above
_ 19. All drugs continue to act in the body until they are changed or excreted. The ability of the body
to excrete drugs via the renal system would be increased by:
A. Reduced circulation and perfusion of the kidney
B. Chronic renal disease
The benefits of buying summaries with Stuvia:
Guaranteed quality through customer reviews
Stuvia customers have reviewed more than 700,000 summaries. This how you know that you are buying the best documents.
Quick and easy check-out
You can quickly pay through credit card or Stuvia-credit for the summaries. There is no membership needed.
Focus on what matters
Your fellow students write the study notes themselves, which is why the documents are always reliable and up-to-date. This ensures you quickly get to the core!
Frequently asked questions
What do I get when I buy this document?
You get a PDF, available immediately after your purchase. The purchased document is accessible anytime, anywhere and indefinitely through your profile.
Satisfaction guarantee: how does it work?
Our satisfaction guarantee ensures that you always find a study document that suits you well. You fill out a form, and our customer service team takes care of the rest.
Who am I buying these notes from?
Stuvia is a marketplace, so you are not buying this document from us, but from seller solutions. Stuvia facilitates payment to the seller.
Will I be stuck with a subscription?
No, you only buy these notes for $19.49. You're not tied to anything after your purchase.
